Therefore, identifying the key PPAT secretion products that trigger PCa onset, progression, and therapy resistance, as well as the factors that can deregulate PPAT function, will be pivotal for better disease management and improved patient clinical outcomes. This evidence concerns the gene PPAT and posterior cortical atrophy.